Home > Insider Trading > Filing (0001479290-23-000015)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1479290	Revance Therapeutics Inc.	RVNC	Pharmaceutical Preparations (2834)	770551645

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1678984	Tobin Schilke	C/O Revance Therapeutics, Inc. 1222 Demonbreun Street, 20Th Floor Nashville TN 37203	Cfo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2023-02-01	3,201	$34.60	54,676	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Employee Stock Option (Right to Buy)	Acquisiton	2023-01-31	50,435	$0.00	50,435	$34.68

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
50,435		2033-01-30	No	4	A	Direct

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan dated November 18, 2022 by Mr. Schilke.
Includes 2,953 shares purchased pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from January 31, 2023, subject to Mr. Schilke's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date.